Diaxonhit Stock Euronext Paris
Equities
FR0004054427
Biotechnology & Medical Research
Sales 2023 | 130M 139M | Sales 2024 * | 138M 148M | Capitalization | 145M 156M |
---|---|---|---|---|---|
Net income 2023 | 4M 4.28M | Net income 2024 * | 9M 9.63M | EV / Sales 2023 | 1.29 x |
Net Debt 2023 * | 8.8M 9.42M | Net cash position 2024 * | 9.9M 10.6M | EV / Sales 2024 * | 0.98 x |
P/E ratio 2023 |
38.3
x | P/E ratio 2024 * |
15
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 59.14% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director of Finance/CFO | 43 | 22-09-30 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director/Board Member | 68 | 09-11-03 | |
Director/Board Member | 67 | 17-06-14 |
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |